- Home
- NAD vs AZTA Comparison
NAD vs AZTA Comparison
Compare NAD & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAD
- AZTA
- Stock Information
- Founded
- NAD 1999
- AZTA 1978
- Country
- NAD United States
- AZTA United States
- Employees
- NAD N/A
- AZTA N/A
- Industry
- NAD Investment Managers
- AZTA Industrial Machinery/Components
- Sector
- NAD Finance
- AZTA Technology
- Exchange
- NAD Nasdaq
- AZTA Nasdaq
- Market Cap
- NAD 2.8B
- AZTA 2.4B
- IPO Year
- NAD N/A
- AZTA 1995
- Fundamental
- Price
- NAD $11.89
- AZTA $44.75
- Analyst Decision
- NAD
- AZTA Buy
- Analyst Count
- NAD 0
- AZTA 4
- Target Price
- NAD N/A
- AZTA $58.75
- AVG Volume (30 Days)
- NAD 595.7K
- AZTA 546.3K
- Earning Date
- NAD 01-01-0001
- AZTA 02-05-2025
- Dividend Yield
- NAD 4.35%
- AZTA N/A
- EPS Growth
- NAD N/A
- AZTA N/A
- EPS
- NAD N/A
- AZTA N/A
- Revenue
- NAD N/A
- AZTA $662,108,000.00
- Revenue This Year
- NAD N/A
- AZTA N/A
- Revenue Next Year
- NAD N/A
- AZTA $6.29
- P/E Ratio
- NAD N/A
- AZTA N/A
- Revenue Growth
- NAD N/A
- AZTA 5.36
- 52 Week Low
- NAD $9.56
- AZTA $38.82
- 52 Week High
- NAD $11.64
- AZTA $67.77
- Technical
- Relative Strength Index (RSI)
- NAD 55.74
- AZTA 31.74
- Support Level
- NAD $11.70
- AZTA $43.93
- Resistance Level
- NAD $11.92
- AZTA $46.10
- Average True Range (ATR)
- NAD 0.07
- AZTA 2.60
- MACD
- NAD 0.00
- AZTA -0.77
- Stochastic Oscillator
- NAD 77.08
- AZTA 7.00
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.